Trial Profile

A Phase 1/2, First-in-Human, Multicenter, Open-Label Study of SQZ-eAPC-HPV as Monotherapy and in Combination With Immune Checkpoint Inhibitor(s) in Patients With HPV16+ Recurrent, Locally Advanced, or Metastatic Solid Tumors

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; SQZ-eAPC-HPV (Primary)
Indications Anal cancer; Cervical cancer; Head and neck cancer; Solid tumours
Focus Adverse reactions; First in man
Acronyms COMMANDER-001
Sponsors SQZ Biotech

21 Feb 2024 Status changed from active, no longer recruiting to discontinued. (Corporate Decision)
03 Nov 2023 According to SQZ media release, data from this study presented at the Society for Immunotherapy of Cancer Annual Meeting 2023.
03 Nov 2023 Results presented in a SQZ Biotech Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com